IP Library Granted Patent US 10,080,767
Granted Patent B2
US 10,080,767 · App. 15/209,561 · Granted Sep 25, 2018

Injectable monophase hydrogels

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: Allergan Industrie SAS
A61K31/738A61K9/0019A61L27/20A61L27/50A61L27/52C08B37/0072C08J3/24C08L5/08C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,080,767
App. No.
15/209,561
Granted
Sep 25, 2018
Kind
B2
Abstract

An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.

Claims (17)

1. An injectable composition prepared by a process comprising the steps of:

providing a first hyaluronic acid salt, having a molecular weight in the range of about 1.1×10 6 Da to about 5×10 6 Da;

providing a second hyaluronic acid salt, having a molecular weight in the range of about 1×10 4 Da to about 9.9·10 5 Da;

mixing the first hyaluronic acid salt and second hyaluronic acid salt to obtain a reaction mixture having an intrinsic viscosity of less than 1900 ml/g, wherein the reaction mixture comprises about 5% by weight to about 30% by weight of the first hyaluronic acid salt;

cross-linking the mixture in an aqueous solvent in the presence of an effective and non-excessive amount of at least one cross-linking agent; and

homogenizing the crosslinked mixture to obtain the injectable composition.

2. The composition of claim 1 having a concentration of hyaluronic acid of between 10 and 40 mg/g.

3. The composition of claim 1 having a concentration of hyaluronic acid of between 20 and 30 mg/g.

4. The composition of claim 1 having a concentration of hyaluronic acid of 26 mg/g.

5. The composition of claim 1 , wherein the cross-linking agent is selected from epichlorohydrin, divinyl sulfone, 1,4-bis(2,3-epoxypropoxy) butane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, aldehydes, and mixtures thereof.

6. The composition of claim 1 , wherein the cross-linking agent is 1,4-butanediol diglycidyl ether (BDDE).

7. The composition of claim 1 wherein the first hyaluronic acid salt has a first intrinsic viscosity and the second hyaluronic acid salt has a second intrinsic viscosity different from the first intrinsic viscosity.

8. The composition of claim 1 wherein first hyaluronic acid salt and the second hyaluronic acid salt are mixed at a weight ratio of 90:10, respectively.

9. The composition of claim 1 , wherein the step of mixing the first hyaluronic acid salt and second hyaluronic acid salt is further conducted in an aqueous solution.

10. The composition of claim 9 , wherein the aqueous solution is a basic solution.

11. The composition of claim 1 , further comprising the step of, after homogenizing, sterilizing the injectable composition.

12. The composition of claim 11 , wherein the step of sterilizing comprises autoclaving the injectable composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2016
From: LEBRETON, PIERRE
To: CORNEAL INDUSTRIE
Reel/Frame 039431/0553 →
CHANGE OF NAME Recorded Aug 15, 2016
From: CORNEAL INDUSTRIE
To: ALLERGAN INDUSTRIE, SAS
Reel/Frame 039431/0665 →
Priority Claims (1)
FR 03 0444 · Apr 10, 2003 · national
Continuity (6)
Continuation 14535220 · Nov 6, 2014
Continuation 14024916 · Sep 12, 2013
Continuation 13566767 · Aug 3, 2012
Continuation 12782488 · May 18, 2010
Division 10552309
Related Publication 20160317571A1 · Nov 3, 2016